The Deacon Herod of Bangalore has reported that India has taken steps to regulate their clinical trails and provide more oversight to ensure that safety and integrity in the clinical trials space happens in India. The Central Drugs Authority will be created which will focus on the regulation of medical devices, export control and a constitution for the CDA. There will be 19 governing members. The CDA will have a licencing branch and every drug, medical device and cosmetic will be required to have a license before exported. Every trial will be registered and have to go through an approval process from a panel of seven CDA members.
Want to get the latest insight on these new regulations and work with your peers to better understand how this will affect your business? Next March, clinic trail representatives from sponsors, partners, CROs and more will meet in Las Vegas for the 23rd Annual Partnerships in Clinical Trials. We're currently producing this year's program, so head to the webpage to find out how you can get involved by speaking, sponsoring or exhibiting. Want to receive the latest updates on the Partnerships agenda? Sign up for email updates!
How important is it that India takes these steps now to better regulate their clinical trials space?
The Partnerships in Clinical Trials Blog focuses optimization intelligence, regulatory trends and globalization strategies for both as sponsors and CROs. It is supported by a number of industry events:
Would you like to guest blog on our site? Or send us feedback? Send an email to firstname.lastname@example.org.